UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
Clinical trial NCT00146042 · COMPLETED
Trial details
- NCT number
- NCT00146042
- Sponsor
- University of Michigan Rogel Cancer Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 1999-03-01
- Primary completion
- 2004-03-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.